CLOs on the Move

ILiAD Biotechnologies

www.iliadbio.com

 
ILiAD Biotechnologies, LLC manufactures vaccines for the prevention and treatment of disease caused by Bordetella Pertussis.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.iliadbio.com
  • 230 East 15th Street Suite 1-A
    New York, NY USA 10003
  • Phone: 954.336.0777

Executives

Name Title Contact Details

Similar Companies

Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.

Avantgen Inc

Avantgen Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Translational Genomics Research Institute

The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.